Company Registration No. 14574842 (England and Wales)
Nova Biochem Ltd
Unaudited accounts
for the year ended 31 December 2025
Nova Biochem Ltd
Unaudited accounts
Contents
Nova Biochem Ltd
Company Information
for the year ended 31 December 2025
Director
Dr Alexander Novitskiy
Company Number
14574842 (England and Wales)
Registered Office
Flat 33 Anchorage Point
42 Cuba Street
London
E14 8NE
England
Accountants
Lanamak Finance Ltd
128 City Road
EC1V 2NX
Nova Biochem Ltd
Statement of financial position
as at 31 December 2025
Cash at bank and in hand
2,903,132
Creditors: amounts falling due within one year
(983,721)
Net current assets
2,010,213
Profit and loss account
(666,548)
Shareholders' funds
2,125,950
For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 31 March 2026 and were signed on its behalf by
Dr Alexander Novitskiy
Director
Company Registration No. 14574842
Nova Biochem Ltd
Notes to the Accounts
for the year ended 31 December 2025
Nova Biochem Ltd is a private company, limited by shares, registered in England and Wales, registration number 14574842. The registered office is Flat 33 Anchorage Point, 42 Cuba Street, London, E14 8NE, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Plant & machinery
20% on cost
Fixtures & fittings
25% on cost
Computer equipment
25% on cost
Share capital and share premium
During the financial year ended 31 December 2025, the company issued 658,005 preference shares of £0.000001 nominal value each at a premium of £3.56 per share. The company also issued 1,162,791 ordinary shares and 523,255 seed shares at nominal value.
Government grants of £232,040 in relation to tangible fixed assets are credited to profit and loss account over the useful lives of the related assets, whereas those in relation to expenditure are credited when the expenditure is charged to profit and loss.
During the year, the company received grant funding of £532,128 from CBE JE (project Splendor), comprising revenue and capital grants covering 60% of eligible expenditure. Grant income is recognised in the profit and loss account in line with the related expenditure incurred, with amounts received in advance deferred and released as costs are recognised. Capital grant income is recognised over the useful economic lives of the related assets.
Conditional research grant
During the year, the company received £500,000 from CCEP to fund a 12-month research and development programme. The funding is conditional on the outcome of the programme.
On successful completion, the funding will convert into equity at a £20 million valuation; otherwise it will be treated as a grant. There is no obligation to repay the funding. Amounts received are recognised as deferred income and released to profit or loss in line with the related research expenditure.
Expenditure on research and development is written off in the year in which it is incurred.
Nova Biochem Ltd
Notes to the Accounts
for the year ended 31 December 2025
4
Tangible fixed assets
Plant & machinery
Fixtures & fittings
Computer equipment
Total
Cost or valuation
At cost
At cost
At cost
At 1 January 2025
4,225
-
2,587
6,812
Additions
89,966
39,173
2,883
132,022
At 31 December 2025
94,191
39,173
5,470
138,834
At 1 January 2025
528
-
654
1,182
Charge for the year
18,838
1,616
1,461
21,915
At 31 December 2025
19,366
1,616
2,115
23,097
At 31 December 2025
74,825
37,557
3,355
115,737
Amounts falling due within one year
6
Creditors: amounts falling due within one year
2025
Taxes and social security
13,054
7
Average number of employees
During the year the average number of employees was 2.